share_log

BMO Capital Maintains Outperform on AstraZeneca, Raises Price Target to $82

Benzinga ·  Apr 26 14:02

BMO Capital analyst Etzer Darout maintains AstraZeneca (NASDAQ:AZN) with a Outperform and raises the price target from $80 to $82.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment